4 Healthcare Stock Stories For Midweek Investment Wellness

GlaxoSmithKline (NYSE:GSK): Closing price $52.95

GlaxoSmithKline and the Biomedical Advanced Research and Development Authority will work jointly in a first of its kind collaboration in support of the development of several antibiotics to fight antibiotic resistance and bioterrorism. This public-private arrangement represents the first time that Health and Human Services has adopted a “portfolio approach” to funding drug development with a private sector firm. This unique partnership will add flexibility to move funding around GSK’s antibacterial portfolio, instead of focusing on only one drug candidate, it will permit medicines to be evaluated for the potential treatment of both conventional and biothreat pathogens. Through the terms, HHS will provide $40 million for the initial 18-month agreement and as much as $200 million should the agreement be renewed over five years.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GSK

Varian Medical Systems (NYSE:VAR): Closing price $68.42

On Wednesday, Varian said it received 510K clearance from the FDA for its diagnostic X-ray image processing workstation that joins radio frequency and digital radiography capabilities on a single platform. Varian’s Nexus DRF Digital X-Ray Imaging System can interface with an array of image receptors, including CCD cameras and commercially available flat-panel image detectors.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VAR

iBio (NYSE:IBIO): Closing price $0.43

iBio announced Wednesday the production of a vaccine candidate for the newly-emerged H7N9 influenza virus by an independent third party lab, employing the iBioLaunch platform. This validation milestone was attained in 21 days, as measured from initial antigen sequence information to purification of recombinant protein. The platform removes the necessity of culturing cells under sterile conditions, eliminates uncertainty regarding yield consistency for large volumes of production, and, subject to regulatory approval, could produce vaccine doses for emergency use against pandemic and bioterrorism threats in weeks as opposed to the months needed with the use of engineered or attenuated virus strains.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

IBIO

Pfizer (NYSE:PFE): Closing price $29.31

Pfizer announced that it will split off its remaining interest in Zoetis (NYSE: ZTS), through an exchange offer. Zoetis was formerly Pfizer’s animal health unit, and concluded its initial public offering in February. Through the exchange offer, Pfizer shareholders can exchange all, some, or none of their shares of Pfizer common stock for shares of Zoetis common stock owned by Pfizer. The exchange offer is expected to be tax-free for participating Pfizer shareholders in the United States, except with respect to cash received in lieu of a fractional share. The completion of the full separation of Zoetis should to be accretive to Pfizer’s earnings per share beginning next year.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PFE

Don’t Miss: Will Obamacare Leave Your Spouse Behind?

More Articles About:   ,  

More from The Cheat Sheet